See more : Chien Wei Precise Technology Co., Ltd. (8092.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Concert Pharmaceuticals, Inc. (CNCE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Concert Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Morarka Finance Limited (MORARKFI.BO) Income Statement Analysis – Financial Results
- Delta Asia International Corporation (6762.TWO) Income Statement Analysis – Financial Results
- Disruptive Acquisition Corporation I (DISA) Income Statement Analysis – Financial Results
- Core One Labs Inc. (COOL.CN) Income Statement Analysis – Financial Results
- Breeze Holdings Acquisition Corp. (BREZW) Income Statement Analysis – Financial Results
Concert Pharmaceuticals, Inc. (CNCE)
About Concert Pharmaceuticals, Inc.
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 32.58M | 7.90M | 1.08M | 10.51M | 143.89M | 174.00K | 66.73M | 8.58M | 25.41M | 12.85M | 19.47M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 32.58M | 7.90M | 1.08M | 10.51M | 143.89M | 174.00K | 66.73M | 8.58M | 25.41M | 12.85M | 19.47M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 87.56M | 61.62M | 59.82M | 43.15M | 30.22M | 36.98M | 28.89M | 27.47M | 21.79M | 24.19M | 23.44M |
| General & Administrative | 22.25M | 18.62M | 19.97M | 22.94M | 21.02M | 14.36M | 13.06M | 11.70M | 8.03M | 7.27M | 7.38M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 22.25M | 18.62M | 19.97M | 22.94M | 21.02M | 14.36M | 13.06M | 11.70M | 8.03M | 7.27M | 7.38M |
| Other Expenses | 283.00K | 301.00K | 306.00K | 0.00 | 0.00 | 0.00 | 0.00 | 20.90M | 12.84M | 0.00 | 0.00 |
| Operating Expenses | 110.09M | 80.55M | 80.09M | 66.09M | 51.24M | 51.34M | 41.94M | 39.17M | 29.82M | 31.46M | 30.81M |
| Cost & Expenses | 110.09M | 80.55M | 80.09M | 66.09M | 51.24M | 51.34M | 41.94M | 39.17M | 29.82M | 31.46M | 30.81M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | -127.00K | 815.00K | 447.00K | 309.00K | 1.15M | 1.67M | 1.86M | 18.00K |
| Depreciation & Amortization | 4.02M | 3.81M | 827.00K | 1.25M | 1.01M | 893.00K | 785.00K | 1.05M | 1.35M | 1.45M | 1.62M |
| EBITDA | -73.49M | -68.84M | -78.19M | -54.46M | 97.16M | -49.83M | 25.70M | -29.50M | -3.04M | -17.14M | -9.68M |
| EBITDA Ratio | -225.57% | -871.15% | -7,259.80% | -518.46% | 67.52% | -28,636.21% | 38.51% | -343.95% | -11.98% | -133.36% | -49.74% |
| Operating Income | -77.51M | -72.65M | -79.02M | -55.58M | 92.65M | -51.17M | 24.79M | -30.60M | -4.41M | -18.61M | -11.35M |
| Operating Income Ratio | -237.92% | -919.35% | -7,336.58% | -529.12% | 64.39% | -29,406.32% | 37.15% | -356.79% | -17.36% | -144.84% | -58.28% |
| Total Other Income/Expenses | -2.54M | -2.20M | 849.00K | -127.00K | 2.69M | 447.00K | -185.00K | -1.10M | -1.65M | -1.83M | 26.00K |
| Income Before Tax | -80.05M | -74.85M | -78.17M | -55.71M | 95.34M | -50.72M | 24.60M | -31.70M | -6.06M | -20.44M | -11.32M |
| Income Before Tax Ratio | -245.72% | -947.24% | -7,257.75% | -530.33% | 66.26% | -29,149.43% | 36.87% | -369.62% | -23.84% | -159.11% | -58.15% |
| Income Tax Expense | 2.54M | -85.00K | -837.00K | 313.00K | -300.00K | 447.00K | 429.00K | 49.00K | 21.00K | 22.00K | 44.00K |
| Net Income | -82.59M | -74.77M | -77.33M | -56.02M | 95.64M | -50.72M | 24.17M | -31.70M | -6.06M | -20.44M | -11.32M |
| Net Income Ratio | -253.53% | -946.17% | -7,180.04% | -533.31% | 66.47% | -29,149.43% | 36.23% | -369.62% | -23.84% | -159.11% | -58.15% |
| EPS | -2.40 | -2.40 | -3.26 | -2.40 | 4.22 | -2.28 | 1.14 | -2.00 | -0.35 | -1.82 | -1.01 |
| EPS Diluted | -2.40 | -2.40 | -3.26 | -2.40 | 4.08 | -2.28 | 1.09 | -2.00 | -0.35 | -1.82 | -1.01 |
| Weighted Avg Shares Out | 34.41M | 31.20M | 23.74M | 23.37M | 22.64M | 22.23M | 21.15M | 15.84M | 17.22M | 11.21M | 11.21M |
| Weighted Avg Shares Out (Dil) | 34.41M | 31.20M | 23.74M | 23.37M | 23.44M | 22.23M | 22.27M | 15.84M | 17.22M | 11.21M | 11.21M |
Concert Pharmaceuticals: Negative Spread But Interesting CVR
Concert Pharmaceuticals, Inc. is a biotech buyout trading at a negative spread but with an interesting CVR attached. The CVR is based on two sales milestones.
Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata
LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. today announced that, after a recent review of deuruxolitinib clinical data by the U.S. Food and Drug Administration (FDA), the FDA determined that deuruxolitinib will maintain its Breakthrough Therapy designation. Deuruxolitinib, an oral Janus kinase...
Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert maintains deuruxolitinib breakthrough therapy designation from FDA for the treatment of alopecia areata.
CNCE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Concert Pharmaceuticals, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) to Sun Pharmaceutical Industries Limited is fair to Concert shareholders. Per the terms of the agreement, Sun Pharma would...
CNCE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Concert Pharmaceuticals, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) to Sun Pharmaceutical Industries Limited is fair to Concert shareholders. Per the terms of the agreement, Sun Pharma would...
SHAREHOLDER ALERT: Weiss Law Reminds AQUA, LPTX, CNCE, and ALBO Shareholders About Its Ongoing Investigations
NEW YORK , Jan. 30, 2023 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:...
Concert (CNCE) Stock Up 17% Last Week on Sun Pharma Buyout Offer
Concert Pharmaceuticals (CNCE) enters into a definitive agreement to be acquired by India-based Sun Pharmaceutical for $576 million. Stock up 17% in the previous week.
Why Concert Pharmaceuticals Stock Rocketed Higher This Week
The company is changing hands in a deal worth at least $576 million.
CONCERT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Concert Pharmaceuticals, Inc. - CNCE
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Concert Pharmaceuticals, Inc. (NasdaqGM: CNCE) to Sun Pharmaceutical Industries Limited. Under...
CONCERT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Concert Pharmaceuticals, Inc. - CNCE
NEW ORLEANS--( BUSINESS WIRE )--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Concert Pharmaceuticals, Inc. (NasdaqGM: CNCE) to Sun Pharmaceutical Industries...
Source: https://incomestatements.info
Category: Stock Reports